These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 8485045)

  • 21. Long-term follow-Up of the italian trial of interferon-alpha versus conventional chemotherapy in chronic myeloid leukemia. The Italian Cooperative Study Group on Chronic Myeloid Leukemia.
    Blood; 1998 Sep; 92(5):1541-8. PubMed ID: 9716581
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Significance of cytogenetic clonal evolution in chronic myelogenous leukemia.
    Majlis A; Smith TL; Talpaz M; O'Brien S; Rios MB; Kantarjian HM
    J Clin Oncol; 1996 Jan; 14(1):196-203. PubMed ID: 8558198
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine.
    Kantarjian HM; O'Brien S; Smith TL; Rios MB; Cortes J; Beran M; Koller C; Giles FJ; Andreeff M; Kornblau S; Giralt S; Keating MJ; Talpaz M
    J Clin Oncol; 1999 Jan; 17(1):284-92. PubMed ID: 10458244
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Treatment of chronic myeloid leukemia using alpha-interferon and hydroxyurea. Study of 30 cases].
    Nese M; de Bellis R; Urtiarte R; Di Landro J
    Sangre (Barc); 1994 Jun; 39(3):183-6. PubMed ID: 7940047
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of chronic myeloid leukemia in chronic phase with autologous stem cell transplantation and alpha-2 interferon: cytogenetic and clinical results.
    Alimena G; Meloni G; de Cuia MR; Rondinelli MB; Lo Coco F; Montefusco E; Mancini M; Pinto R; Nanni M; Cedrone M
    Leuk Lymphoma; 1993; 11 Suppl 1():281-91. PubMed ID: 7902746
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders.
    Bonifazi F; de Vivo A; Rosti G; Guilhot F; Guilhot J; Trabacchi E; Hehlmann R; Hochhaus A; Shepherd PC; Steegmann JL; Kluin-Nelemans HC; Thaler J; Simonsson B; Louwagie A; Reiffers J; Mahon FX; Montefusco E; Alimena G; Hasford J; Richards S; Saglio G; Testoni N; Martinelli G; Tura S; Baccarani M; ; ; ; ; ; ; ;
    Blood; 2001 Nov; 98(10):3074-81. PubMed ID: 11698293
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase.
    Kantarjian H; O'Brien S; Cortes J; Shan J; Giles F; Garcia-Manero G; Verstovsek S; Faderl S; Rios MB; Talpaz M
    Cancer; 2003 Oct; 98(7):1430-7. PubMed ID: 14508830
    [TBL] [Abstract][Full Text] [Related]  

  • 28. GM-CSF can improve the cytogenetic response obtained with interferon-alpha therapy in patients with chronic myelogenous leukemia.
    Cortes J; Kantarjian H; O'Brien S; Kurzrock R; Keating M; Talpaz M
    Leukemia; 1998 Jun; 12(6):860-4. PubMed ID: 9639411
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An extremely delayed cytogenetic response to interferon-alpha in a patient with chronic myeloid leukaemia.
    Whiteway AJ; Reid CD; Cross NC
    Leukemia; 1997 Apr; 11(4):614-6. PubMed ID: 9096705
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intensive combination chemotherapy and autologous bone marrow transplantation leads to the reappearance of Philadelphia chromosome-negative cells in chronic myelogenous leukemia.
    Kantarjian HM; Talpaz M; LeMaistre CF; Spinolo J; Spitzer G; Yau J; Dicke K; Jagannath S; Deisseroth AB
    Cancer; 1991 Jun; 67(12):2959-65. PubMed ID: 1675151
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Southern technique and cytogenetics are complementary and must be used together in the evaluation of Ph1, M-BCR positive chronic myeloid leukemia (CML) patients treated with alpha interferon (IFN-alpha).
    Steegmann JL; Requena MJ; Casado LF; Pico M; Peñarrubia MJ; Ferro MT; Resino M; Fernandez-Rañada JM
    Am J Hematol; 1996 Nov; 53(3):169-74. PubMed ID: 8895687
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The impact of the combination of baseline risk group and cytogenetic response on the survival of patients with chronic myeloid leukemia treated with interferon alpha.
    Hasford J; Pfirrmann M; Shepherd P; Guilhot J; Hehlmann R; Mahon FX; Kluin-Nelemans HC; Ohnishi K; Steegmann JL; Thaler J
    Haematologica; 2005 Mar; 90(3):335-40. PubMed ID: 15749665
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term treatment of chronic myelogenous leukemia with different interferons: results from three studies.
    Niederle N; Kloke O; Wandl UB; Becher R; Moritz T; Opalka B
    Leuk Lymphoma; 1993 Jan; 9(1-2):111-9. PubMed ID: 8477190
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Conversion of interferon-induced, long-term cytogenetic remissions in chronic myelogenous leukemia to polymerase chain reaction negativity.
    Kurzrock R; Estrov Z; Kantarjian H; Talpaz M
    J Clin Oncol; 1998 Apr; 16(4):1526-31. PubMed ID: 9552062
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients.
    Talpaz M; Kantarjian H; Kurzrock R; Trujillo JM; Gutterman JU
    Ann Intern Med; 1991 Apr; 114(7):532-8. PubMed ID: 2001086
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Analysis of cytogenetic response in Ph+ chronic myeloid leukemia patients treated with interferon alpha].
    Hong H; Qiu JY; Lai YY; Shi Y; He Q; Dang H; Lu DP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Jun; 11(3):269-73. PubMed ID: 12844411
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.
    Kantarjian HM; O'Brien S; Cortes J; Giles FJ; Rios MB; Shan J; Faderl S; Garcia-Manero G; Ferrajoli A; Verstovsek S; Wierda W; Keating M; Talpaz M
    Cancer; 2003 Dec; 98(12):2636-42. PubMed ID: 14669283
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Initial treatment of chronic myelogenous leukemia--interferon or bone marrow transplantation].
    Urabe A
    Gan To Kagaku Ryoho; 1999 Sep; 26(10):1381-6. PubMed ID: 10500523
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa.
    Mahon FX; Delbrel X; Cony-Makhoul P; Fabères C; Boiron JM; Barthe C; Bilhou-Nabéra C; Pigneux A; Marit G; Reiffers J
    J Clin Oncol; 2002 Jan; 20(1):214-20. PubMed ID: 11773172
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
    Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.